Market Reading & Resources
Investing Books

Investment ideas and market fundamentals for readers who prefer a thesis to a hot tip.

Click to View

Sponsor funding complete. Trade on.

AI Healthcare Stocks Merck, Amgen, and Johnson & Johnson Outperform

Aug 30, 2026
AI Healthcare Stocks Merck, Amgen, and Johnson & Johnson Outperform

Artificial intelligence is increasingly becoming a practical tool in , moving beyond mere buzzwords to tangible applications in drug discovery and surgical procedures. This shift presents a unique opportunity as biotech and healthcare companies harness to expedite drug development, making it faster, cheaper, and more precise. The ongoing demand for healthcare ensures that these businesses remain integral to the economy, especially as they innovate and adapt to new technologies.

Among the top performers in this sector are Merck & Company, Amgen, and Johnson & Johnson, all of which are utilizing AI to enhance their operations while also providing to investors. According to Barchart’s Stock Screener, these companies have shown remarkable stock performance, significantly outpacing the .

Market Reading & Resources
Investing Books
Click to View
Market History
Click to View
Trading Journals
Click to View

Sponsor funding complete. Trade on.

Merck & Company, known for its medicines and vaccines, has seen its stock rise 42% this year, outperforming the S&P 500 by approximately 29 percentage points. The company is also expanding its AI capabilities through a partnership with Google Cloud, which supports its research and manufacturing processes. Additionally, Merck offers a forward annual dividend of $3.40, yielding about 2.17%. Analysts rate Merck as a “Moderate Buy,” indicating potential for further growth.

Amgen, another key player in the biotech space, focuses on developing treatments for various diseases, particularly cancer. The company is leveraging NVIDIA's technology to enhance its drug discovery processes. Amgen's stock has increased by 34% year-to-date, surpassing the market by around 21 percentage points. It also pays an annual dividend of $10.08 per share, translating to a yield of approximately 2.3%. Analysts have a consensus rating of “Moderate Buy” for Amgen, although its stock is nearing its high target price.

Johnson & Johnson, a well-known name in healthcare, is actively involved in innovative medical technologies, including AI initiatives aimed at optimizing surgical workflows. The company’s stock has risen 28% this year, outperforming the S&P 500 by 15 percentage points. Johnson & Johnson offers an annual dividend of $5.36 per share, yielding about 2%. Analysts also rate JNJ stock as a “Moderate Buy,” with a modest upside projected over the next year.

As healthcare continues to evolve, these companies exemplify how AI can drive innovation while providing steady dividends. For investors seeking exposure to both the healthcare sector and the AI boom, Merck, Amgen, and Johnson & Johnson present compelling opportunities worth exploring.

Market Reading & Resources
Investing Books

Investment ideas and market fundamentals for readers who prefer a thesis to a hot tip.

Click to View
Market History

Booms, bubbles, and spectacular miscalculations. The market has quite a back catalog.

Click to View

Sponsor funding complete. Trade on.

Recommended for You
AI Stocks Comprise 49% of S&P 500, Highlighting Market Concentration Risks
US Tech Stocks Oct 20, 2026

AI Stocks Comprise 49% of S&P 500, Highlighting Market Concentration Risks

AI-linked companies now represent 49% of the S&P 500, marking the second-highest concentration in the index's history. This trend raises…

Market Reading & Resources
Investing Books

Investment ideas and market fundamentals for readers who prefer a thesis to a hot tip.

Click to View
Market History

Booms, bubbles, and spectacular miscalculations. The market has quite a back catalog.

Click to View
Trading Journals

Record the thesis, the trade, and what actually happened. Hindsight could use some paperwork.

Click to View
Options Pricing & Volatility Books

References on options, pricing, and volatility for the research shelf. A little more homework before the next complicated position.

Click to View
Market Structure & Order-Flow Books

Books on market structure, liquidity, and order flow. Understand the machinery behind the screen, not just the flashing numbers.

Click to View
Trading Psychology & Behavioral Finance

Decision-making, cognitive biases, and trading discipline. Conviction is useful; confusing it with evidence is rather less so.

Click to View

Sponsor funding complete. Trade on.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)